Journal of epidemiology and global health · 2025
Advanced Stage Disease Progression and Mortality Rate Before and After the Implementation of the Universal Test and Treat Strategy (UTT) for HIV Patients in Ethiopia: A Systematic Review and Meta-Analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Moges Sisay, Lajore Bereket Aberham, Debesay Betelhem Asmerom, Belato Degefa Tadele
Аннотация
BACKGROUND: The universal test and treat (UTT) program, is a strategy for eliminating HIV and, it involves screening all populations at risk for HIV infection, initiating early treatment for those diagnosed HIV positive, monitoring and maintaining treatment, and Retaining patients in care. Therefore, this meta-analysis evaluates the impact of the Test-and-Treat strategy on HIV-positive patients in Ethiopia, focusing on mortality rates and disease progression.
METHODS: A systematic literature search was conducted using databases such as PubMed, Embase, African Journals Online (AJOL), Google Scholar, and Web of Science. Data were classified into two periods: 2005 to 2015 (before test and treat era) and 2016-2024 (after test and treat strategy). Eligible studies included cohort and cross-sectional designs providing distinct data for these timeframes, irrespective of publication year, to assess reductions in mortality and disease progression (WHO Stage III or IV). Study quality and bias were assessed using the Newcastle-Ottawa Scale (NOS), ensuring rigorous evaluation across selection, comparability, and outcome domains. A random-effects model was employed for the meta-analysis.
RESULTS: The pooled mortality rate decreased significantly from 21% (95% CI: 14-29%) in the before test and treat period to 9% (95% CI: 6-12%) after the test and treat period, representing a 57.14% reduction. The proportion of patients in WHO Stage III declined from 47% (95% CI: 39-54%) to 21% (95% CI: 16-26%), a reduction of 55.32%. Similarly, the prevalence of WHO Stage IV decreased from 14% (95% CI: 12-16%) to 8% (95% CI: 5-10%), reflecting a 42.86% reduction.
CONCLUSION: The test and treat strategy in Ethiopia has substantial reductions in mortality and disease progression. These results underscore the effectiveness of early, universal treatment initiation in improving patient survival and reducing the burden of HIV-related complications.
METHODS: A systematic literature search was conducted using databases such as PubMed, Embase, African Journals Online (AJOL), Google Scholar, and Web of Science. Data were classified into two periods: 2005 to 2015 (before test and treat era) and 2016-2024 (after test and treat strategy). Eligible studies included cohort and cross-sectional designs providing distinct data for these timeframes, irrespective of publication year, to assess reductions in mortality and disease progression (WHO Stage III or IV). Study quality and bias were assessed using the Newcastle-Ottawa Scale (NOS), ensuring rigorous evaluation across selection, comparability, and outcome domains. A random-effects model was employed for the meta-analysis.
RESULTS: The pooled mortality rate decreased significantly from 21% (95% CI: 14-29%) in the before test and treat period to 9% (95% CI: 6-12%) after the test and treat period, representing a 57.14% reduction. The proportion of patients in WHO Stage III declined from 47% (95% CI: 39-54%) to 21% (95% CI: 16-26%), a reduction of 55.32%. Similarly, the prevalence of WHO Stage IV decreased from 14% (95% CI: 12-16%) to 8% (95% CI: 5-10%), reflecting a 42.86% reduction.
CONCLUSION: The test and treat strategy in Ethiopia has substantial reductions in mortality and disease progression. These results underscore the effectiveness of early, universal treatment initiation in improving patient survival and reducing the burden of HIV-related complications.